Mammogram plus MRI or ultrasound catches more cancer

Share this article:
Mammogram Plus MRI or Ultrasound Catches More Cancer
Mammogram Plus MRI or Ultrasound Catches More Cancer

(HealthDay News) -- The addition of an ultrasound or magnetic resonance imaging (MRI) to annual mammography results in a higher rate of detection of incident breast cancers, according to a study published in the April 4 issue of the Journal of the American Medical Association.

Wendie A. Berg, M.D., Ph.D., of Magee-Womens Hospital in Pittsburgh, and colleagues followed 2,809 women with elevated cancer risk and dense breast tissue. A total of 2,662 women underwent three annual screens with mammography and ultrasound in randomized order. After three rounds of both screenings, women could choose to undergo an MRI.

The researchers found that supplemental incidence screening ultrasound identified 3.7 cancers per 1,000 screens (P < 0.001). For mammography plus ultrasound, the sensitivity was 0.76; specificity, 0.84; and positive predictive value (PPV3), 0.16. The corresponding values for mammography alone were 0.52, 0.91, and 0.38 (P < 0.001 for all comparisons). Breast cancer was diagnosed in 2.6 percent of the 612 MRI participants, with a supplemental yield of 14.7 per 1,000 (P = 0.004). For MRI and mammography plus ultrasound the sensitivity was 1.00; specificity, 0.65; and PPV3, 0.19. For the participants who underwent MRI, the sensitivity of combined mammography and ultrasound was 0.44 (P = 0.004); the specificity was 0.84 (P < 0.001); and the PPV3 was 0.18 (P = 0.98). To detect one cancer, the number of screens needed was 127 for mammography; 234 for supplemental ultrasound; and 68 for MRI after negative mammography and ultrasound results.

"The addition of screening ultrasound or MRI to mammography in women at increased risk of breast cancer resulted in not only a higher cancer detection yield but also an increase in false-positive findings," the authors write.

Several authors disclosed financial ties to the medical device industry.

Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

What is this?

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Idelalisib approved by FDA for three types of blood cancer

Idelalisib approved by FDA for three types of ...

Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, but label warns drug may be toxic to the liver.

Physicians cautioned about counterfeit medical devices

Physicians cautioned about counterfeit medical devices

Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices.

Women undergoing morcellation have in 27 in 10k uterine cancer prevalence

Women undergoing morcellation have in 27 in 10k ...

For women undergoing hysterectomy by morcellation, the prevalence of uterine cancers is 27 per 10,000, with increased prevalence with advanced age, according to a research letter published online.